https://ipharmag.com/article/foundayo-vs-wegovy-pill-glp1-weight-loss-pills-compared iPharmag en 2026-09-25T11:15:25+00:00 Foundayo vs. the Wegovy Pill: How the Two GLP-1 Weight-Loss Pills Compare https://ipharmag.com/article/roche-sefaxersen-iga-nephropathy-phase3-kidney iPharmag en 2026-09-25T10:59:37+00:00 Roche’s Kidney Drug Posts Positive Phase 3 Data in a Crowding IgA Nephropathy Race https://ipharmag.com/article/iga-nephropathy-explained-symptoms-causes-treatment iPharmag en 2026-09-25T10:59:37+00:00 IgA Nephropathy Explained: Symptoms, Causes, Diagnosis and the New Treatments https://ipharmag.com/article/fda-panel-endorses-grail-galleri-multi-cancer-test iPharmag en 2026-09-25T10:59:37+00:00 FDA Advisers Endorse the First Blood Test That Screens for Many Cancers https://ipharmag.com/article/osteoporosis-drug-development-reinvigorated-interest iPharmag en 2026-09-23T16:00:57+00:00 After Years of Neglect, Osteoporosis Drugs Are Suddenly Hot Again https://ipharmag.com/article/europe-biotech-decline-pharma-chairs-alarm iPharmag en 2026-09-23T16:00:57+00:00 Nine Pharma Chairs Warn Europe Is Losing the Biotech Race https://ipharmag.com/article/boomray-novartis-900m-radioligand-therapy-deal iPharmag en 2026-09-23T16:00:57+00:00 Novartis Pays Up to $900M for a Chinese Biotech’s Radioactive Cancer Drug https://ipharmag.com/article/boehringer-envisagenics-1-billion-rna-splicing-cancer-ai iPharmag en 2026-09-23T16:00:57+00:00 Boehringer Bets Over $1B on AI That Reads a Hidden Layer of Cancer Biology https://ipharmag.com/article/basecamp-research-140m-ai-designed-drugs-eden iPharmag en 2026-09-23T16:00:57+00:00 Anthropic- and Nvidia-Backed Startup Raises $140M to Let AI Design Living Medicines